Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal

NCT02062190 is registered in ClinicalTrials.gov with Federal University of Rio Grande do Sul as lead sponsor.

NCT NCT02062190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02062190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal
Lead sponsor
Federal University of Rio Grande do Sul
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
May 31, 2015
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia